Royalty Pharma (RPRX)

$30.75 0.6%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    2

  • Fundamental

    4

  • Technical

    7

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Royalty Pharma, AI stock picks, stock alerts and much more.

Sign up

RPRX AI Stock Analysis

AI stock analysis for RPRX is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Royalty Pharma (RPRX) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

RPRX Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Royalty Pharma (RPRX), currently trading at $30.75, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About RPRX

LSE

  • Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.

  • Symbol

    RPRX

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    13.7B

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX		 $22.78
0.5%
6
INO Inovio Pharmaceuticals
INO		 $2.08
8.9%
4
MRNA Moderna
MRNA		 $34.06
0.9%
4
AVXL Anavex Life Sciences
AVXL		 $9.21
9.3%
6
BBIO BridgeBio Pharma
BBIO		 $33.79
0.9%
7

News

Royalty Pharma: Key Strategic Updates To Be Priced In

Royalty Pharma: Key Strategic Updates To Be Priced In
January 15, 2025. seekingalpha.com
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors

Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
January 13, 2025. zacks.com
Royalty Pharma simplifies corporate structure with $1.1 bln deal

Royalty Pharma simplifies corporate structure with $1.1 bln deal
January 10, 2025. reuters.com
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
January 10, 2025. globenewswire.com

RPRX Alternative Data

News Mentions

Sign up to access

LinkedIn Followers

Sign up to access

Job Postings

Sign up to access

LinkedIn Employees

Sign up to access

Web Traffic

Sign up to access

RPRX Financials

RPRX Key Metrics

  • Total Revenue

    $564.7M

  • Net Income

    $544M

  • Earnings per Share

    $1.22

  • Free cash flow

    $1.5B

  • EBITDA

    $735.1M

  • EBITDA Ratio

    1.30173

  • Total Assets

    $18B

RPRX 2-year Revenue & Income
RPRX 2-year Free Cash Flow

RPRX Technicals

RPRX SMA
RPRX RSI

FAQ

What's the current price of Royalty Pharma (RPRX) Stock?
The price of an Royalty Pharma (RPRX) share is $30.75.

What's the market cap of Royalty Pharma?
The current market cap of Royalty Pharma is 13.7B.

Should I buy or sell RPRX?
Royalty Pharma shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Royalty Pharma is better viewed as a hold or accumulate position while waiting for further developments.

Is Royalty Pharma a good investment?
The current analysis of Royalty Pharma's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Royalty Pharma's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Royalty Pharma (RPRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Royalty Pharma stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Royalty Pharma (RPRX) that investors often compare it to?
Royalty Pharma (RPRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Royalty Pharma's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Royalty Pharma's stock price to be around $28.92 in 2026. Starting from the current price of $30.75, this represents a 6% change in price, indicating a bearish outlook for the stock.

How to buy Royalty Pharma (RPRX) Stock?
Royalty Pharma stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Royalty Pharma shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.